Heron M. Deaths: leading causes for 2016. National vital statistics reports: vol 67 no 6. Hyattsville, MD. National Center for Health Statistics. 2018.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2019). https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed April 2019.
Pearce JA, Shiltz DL, Ding Q. Effectiveness and safety comparison for systemic corticosteroid therapy with and without inhaled corticosteroids for COPD exacerbation management. Ann Pharmacother. 2018;52(11):1070–7.
Baker JM, Pace HA, Ladesich JB, Simon SD. Evaluation of the impact of corticosteroid dose on the incidence of hyperglycemia in hospitalized patients with an acute exacerbation of chronic obstructive pulmonary disease. Hosp Pharm. 2016;51(4):296–304.
Steuber T, Shiltz D. Single-center retrospective evaluation of inhaled corticosteroid use for chronic obstructive pulmonary disease exacerbation patients receiving systemic corticosteroids. Hosp Pharm. 2016;51(10):841–6.
Lindenauer PK, Shieh MS, Pekow PS, Stefan MS. Use and outcomes associated with long-acting bronchodilators among patients hospitalized for chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11(8):1186–94.
Amin AN, Bollu V, Stensland MD, Netzer L, Ganapathy V. Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease. Am J Health-Syst Pharm. 2018;75(6):359–66.
Peters JI, Shelledy DC, Jones AP, Lawson RW, Davis CP, LeGrand TS. A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma. Chest. 2000;118:313–20.
Kerstjens HA, Bantje TA, Luursema PB, Sinninghe Damste HE, de Jong JW. Effects of short-acting bronchodilators added to maintenance tiotropium therapy. Chest. 2007;132:1493–9.
Cazzola M, Santus P, D’Adda A, Pizzolato S, DiMarco F, Centanni S. Acute effects of higher than standard doses of salbutamol and ipratropium on tiotropium-induced bronchodilation in patients with stable COPD. Pulm Pharmacol Ther. 2009;22:177–82.
Kitaguchi Y, Fujimoto K, Komatsu Y, Hanaoka M, Honda T, Kubo K. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators. Respir Med. 2013;107:394–400.
Cazzola M, Noschese P, Michele FD, D’Amato G, Matera MG. Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD. Respir Med. 2006;100:212–7.
Salpeter SR, Ormiston T, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD. Chest. 2004;125:2309–21.
Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med. 1996;125:605–13.
Kopsaftis ZA, Sulaiman NS, Mountain OD, Carson-Chahhoud KV, Phillips PA, Smith BJ. Short-acting bronchodilators for the management of acute exacerbations of chronic obstructive pulmonary disease in the hospital setting: systemic review. Syst Rev. 2018;7:213.
McCrory DC, Brown CD. Anticholinergic bronchodilators versus beta2-sympathomimmetic agents for acute exacerbations of chronic obstructive disease. Cochrane Database Syst Rev. 2002;4:CD003900.
Beltaief K, Msolli MA, Zorgati A, Sekma A, Fakhfakh M, Marzouk MB, et al. Nebulized terbutaline and ipratropium bromide versus terbutaline alone in acute exacerbation of chronic obstructive pulmonary disease requiring noninvasive ventilation: a randomized double-blind controlled trial. Acad Emerg Med. 2019;26(4):434–42.
Kumar SD, Brieva JL, Danta I, Wanner A. Transient effect of inhaled fluticasone on airway mucosal blood flow in subjects with and without asthma. Am J Respir Crit Care Med. 2000;161:918–21.
Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;9:CD001288.
Mirici A, Meral M, Akgun M. Comparison of the efficacy of nebulized budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Invest. 2003;23(1):55–62.
Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J. 2007;29(4):660–7.
Gunen H, Mirici A, Meral M, Akgun M. Steroids in acute exacerbations of chronic obstructive pulmonary disease: are nebulised and systemic forms comparable? Curr Opin Pulm Med. 2009;15:133–7.
Morice AH, Morris D, Lawson-Matthew B. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther. 1996;60:675–8.
Ding Z, Li X, Youjin L, Rong G, Yang R, Zhang R, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous methylprednisolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2016;121:39–47.
Sakaan S, Ulrich D, Luo J, Finch CK, Self TH. Inhaler use in hospitalized patients with chronic obstructive pulmonary disease or asthma: assessment of wasted doses. Hosp Pharm. 2015;50(5):386–90.
Singh S, Loke Y, Enright P, Furberg CD. Pro-arrhythmic and pro-ischemic effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114–6.
Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;10(3):CD010115.
Singh S, Furberg CD. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease. Arch Intern Med. 2011;171:920–2.
Colice GL, Carnathan B, Sung J, Paramore LC. A respiratory therapist-directed protocol for managing inpatients with asthma and COPD incorporating a long-acting bronchodilator. J Asthma. 2005;1:29–34.
Jinjuvadia C, Jinjuvadia R, Mandapakala C, Durairajan N, Liangpunsakul S, Soubani A. Trends in outcomes, financial burden, and mortality for acute exacerbation of chronic obstructive pulmonary disease (COPD) in the United States from 2002–2010. COPD. 2017;14(1):72–9.
Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154:407–12.
Modrykamien AM, Stoller JK. The scientific basis for protocol-directed respiratory care. Respir Care. 2013;58(10):1662–8.